Medical tech firm Sanara's Q3 revenue misses estimates after Tissue Health Plus unit closure

Sanara MedTech

12/11/2025 12:10

Overview

Sanara Q3 revenue grows 22% yr/yr to $26.3 mln, missing analyst expectations

Net income from continuing operations improved to $0.8 mln from a loss last year

Company ceases Tissue Health Plus operations for strategic realignment

Outlook

Company expects strong, sustainable revenue growth for remainder of 2025

Result Drivers

SOFT TISSUE SALES - Revenue growth driven by 24% increase in sales of soft tissue repair products, including CellerateRX Surgical and BIASURGE

STRATEGIC REALIGNMENT - Ceased operations of Tissue Health Plus to enhance operational efficiency and focus on core surgical business

DISTRIBUTION NETWORK EXPANSION - Growth attributed to development of relationships with independent distributors and expansion into new healthcare facilities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$26.30 mln
$26.60 mln (2 Analysts)
Q3 EPS
-$3.40


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Sanara Medtech Inc is $50.00, about 43.9% above its November 11 closing price of $28.04

Press Release: ID:nGNX4lbcxH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)